Is It Too Late To Consider Definium Therapeutics (DFTX) After Its Strong 1 Year Run? [Yahoo! Finance]
Definium Therapeutics, Inc. - Common Shares (DFTX)
Company Research
Source: Yahoo! Finance
If you are wondering whether Definium Therapeutics at US$22.68 still offers value or if most of the opportunity is already priced in, the starting point is to look closely at what the market is paying for its fundamentals. The stock has recently recorded returns of 5.3% over 7 days, 28.6% over 30 days and 66.3% year to date, with a 293.1% return over 1 year and 474.2% over 3 years, set against a 57.0% decline over 5 years. These moves have put Definium Therapeutics on the radar of more investors, and recent coverage has focused on how the share price compares with estimates of fair value and balance sheet strength. This context is important because it frames whether recent momentum reflects changing risk perceptions or simply a catch up to underlying fundamentals. On Simply Wall St's 6 point valuation check, Definium Therapeutics scores 3 out of 6 , so the next step is to unpack how different valuation approaches line up, and then finish with a broader way of thinking about wha
Show less
Read more
Impact Snapshot
Event Time:
DFTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DFTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DFTX alerts
High impacting Definium Therapeutics, Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
DFTX
News
- Definium: 'Strong Buy' Maintained On Several Anticipated 2026 Milestones [Seeking Alpha]Seeking Alpha
- Definium Therapeutics Teases 3 Phase III DT120 Readouts in 2026, Starting Late Q2 MDD Data [Yahoo! Finance]Yahoo! Finance
- Definium Therapeutics (DFTX) was given a new $30.00 price target by Stifel Nicolaus.MarketBeat
- Definium Therapeutics (DFTX) was given a new $38.00 price target by Canaccord Genuity Group Inc..MarketBeat
- Definium Therapeutics (DFTX) is now covered by Piper Sandler. They set an "overweight" rating and a $49.00 price target on the stock.MarketBeat
DFTX
Earnings
- 2/26/26 - Miss
DFTX
Sec Filings
- 3/26/26 - Form 4
- 3/26/26 - Form 4
- 3/26/26 - Form 4
- DFTX's page on the SEC website